Expertise in
36
conditions

Dr. Fasahat Hamzavi

Dermatology
Hamzavi Pharmacy
2950 Keewahdin Rd, 
Fort Gratiot, MI 
Expertise in
36
conditions
Hamzavi Pharmacy
2950 Keewahdin Rd, 
Fort Gratiot, MI 

Overview

Fasahat Hamzavi is a Dermatologist in Fort Gratiot, Michigan. Dr. Hamzavi is highly rated in 36 conditions, according to our data. His top areas of expertise are Universal Acquired Melanosis, Liver Spots, Actinic Keratosis, and Warts.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Dermatology

Licenses

Dermatology in MI

Hospital Affiliations

Mclaren Port Huron

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Hamzavi Pharmacy
2950 Keewahdin Rd, Fort Gratiot, MI 48059

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Combination product
Study Phase: Phase 3
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
Enrollment Status: Completed
Publish Date: February 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

1 Total Publications

Neonatal dermatophytosis: report of a case and review of the literature.
Neonatal dermatophytosis: report of a case and review of the literature.
Journal: Pediatric dermatology
Published: April 21, 2011
Similar Doctors
Expertise in
31
conditions
Dr. Iltefat Hamzavi
Dermatology
Expertise in
31
conditions
Dr. Iltefat Hamzavi
Dermatology

Hamzavi Dermatology

43151 Dalcoma Drive, Suite 4, 
Clinton Township, MI 
 (0.1 miles away)
586-286-8720
Experience:
30+ years
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Iltefat Hamzavi is a Dermatologist in Clinton Township, Michigan. Dr. Hamzavi has been practicing medicine for over 30 years is highly rated in 31 conditions, according to our data. His top areas of expertise are Vitiligo, Hidradenitis Suppurativa, Hypomelanotic Disorder, and Acne. Dr. Hamzavi is currently accepting new patients.

Expertise in
14
conditions
Dr. Linda Stein
Dermatology
Expertise in
14
conditions
Dr. Linda Stein
Dermatology

Henry Ford Medical Center-Farmington Road

6530 Farmington Rd, 
West Bloomfield, MI 
 (21.8 miles away)
248-661-8240
Languages Spoken:
English
See accepted insurances

Linda Stein is a Dermatologist in West Bloomfield, Michigan. Dr. Stein is highly rated in 14 conditions, according to our data. Her top areas of expertise are Acne, Rosacea, Plaque Psoriasis, and Psoriasis.

Expertise in
13
conditions
Dr. David Ozog
Dermatology
Expertise in
13
conditions
Dr. David Ozog
Dermatology

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (18.2 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances

David Ozog is a Dermatologist in Detroit, Michigan. Dr. Ozog is highly rated in 13 conditions, according to our data. His top areas of expertise are Keloids, Muir-Torre Syndrome, Basal Cell Skin Cancer, and Bowen's Disease.

Frequently Asked Questions about Dr. Fasahat Hamzavi

How do I make an appointment with Dr. Fasahat Hamzavi?

You can book an appointment with Dr. Fasahat Hamzavi by calling their office at 810-455-1600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Fasahat Hamzavi a top-rated expert for Universal Acquired Melanosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Fasahat Hamzavi is classified as an Distinguished expert for Universal Acquired Melanosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Fasahat Hamzavi specialize in?

While Dr. Fasahat Hamzavi is a Dermatology, they have specific expertise in Universal Acquired Melanosis, Liver Spots, and Actinic Keratosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Fasahat Hamzavi participate in research or clinical trials?

Yes. Dr. Fasahat Hamzavi has published 1 articles and abstracts on conditions like Universal Acquired Melanosis. You can view a list of Dr. Fasahat Hamzavi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Fasahat Hamzavi accept my insurance?

Dr. Fasahat Hamzavi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 810-455-1600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hamzavi's expertise for a condition
ConditionClose
    View All 32 Advanced Conditions
    View All 63 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile